Eben I. Lichtman

835 total citations
30 papers, 626 citations indexed

About

Eben I. Lichtman is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Eben I. Lichtman has authored 30 papers receiving a total of 626 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 11 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Eben I. Lichtman's work include Multiple Myeloma Research and Treatments (13 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and CAR-T cell therapy research (4 papers). Eben I. Lichtman is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and CAR-T cell therapy research (4 papers). Eben I. Lichtman collaborates with scholars based in United States, Australia and Taiwan. Eben I. Lichtman's co-authors include Hidde L. Ploegh, Edda Fiebiger, Martijn Verdoes, Paul J. Galardy, Celia R. Berkers, Kenneth C. Anderson, Huib Ovaa, Benedikt M. Kessler, Simon M. Helfgott and Gianpietro Dotti and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Methods.

In The Last Decade

Eben I. Lichtman

27 papers receiving 614 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eben I. Lichtman United States 8 292 266 121 117 58 30 626
Thomas Gelzleichter United States 17 253 0.9× 115 0.4× 304 2.5× 18 0.2× 39 0.7× 32 827
Shripad Sinari United States 13 407 1.4× 216 0.8× 131 1.1× 241 2.1× 78 1.3× 22 891
Zhongzheng Zhu China 14 322 1.1× 180 0.7× 35 0.3× 8 0.1× 46 0.8× 59 634
Xiaohong Chang China 18 318 1.1× 130 0.5× 215 1.8× 11 0.1× 24 0.4× 78 872
Chi-De Chen Taiwan 12 470 1.6× 129 0.5× 45 0.4× 21 0.2× 25 0.4× 13 857
Shwu‐Luan Lee United States 6 353 1.2× 118 0.4× 79 0.7× 219 1.9× 34 0.6× 7 655
Erandi Rajagurubandara United States 11 265 0.9× 289 1.1× 95 0.8× 65 0.6× 93 1.6× 12 787
Nigel J. Parr United Kingdom 17 399 1.4× 201 0.8× 54 0.4× 157 1.3× 62 1.1× 42 917
Takashi Shinya Japan 8 107 0.4× 168 0.6× 45 0.4× 99 0.8× 35 0.6× 8 527
Rolf D. Pettersen Norway 15 191 0.7× 65 0.2× 352 2.9× 29 0.2× 47 0.8× 22 620

Countries citing papers authored by Eben I. Lichtman

Since Specialization
Citations

This map shows the geographic impact of Eben I. Lichtman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eben I. Lichtman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eben I. Lichtman more than expected).

Fields of papers citing papers by Eben I. Lichtman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eben I. Lichtman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eben I. Lichtman. The network helps show where Eben I. Lichtman may publish in the future.

Co-authorship network of co-authors of Eben I. Lichtman

This figure shows the co-authorship network connecting the top 25 collaborators of Eben I. Lichtman. A scholar is included among the top collaborators of Eben I. Lichtman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eben I. Lichtman. Eben I. Lichtman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kapoor, Prashant, Nitya Nathwani, Tomáš Jelı́nek, et al.. (2024). An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. European Journal Of Haematology. 113(5). 593–605. 1 indexed citations
3.
Zhou, Xi, Christopher D. Baggett, Sascha A. Tuchman, et al.. (2024). Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis. Clinical Lymphoma Myeloma & Leukemia. 24(9). 611–620. 1 indexed citations
4.
5.
Jensen, Christopher E., Allison M. Deal, Kirsten A. Nyrop, et al.. (2023). Geriatric assessment-guided interventions for older adults with multiple myeloma: A feasibility and acceptability study. Journal of Geriatric Oncology. 15(2). 101680–101680. 3 indexed citations
6.
Heiling, Hillary, Allison M. Deal, Christopher E. Jensen, et al.. (2022). Longitudinal Analysis of Patient-Reported Cognitive Function in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 22(12). 920–927. 6 indexed citations
7.
Jensen, Christopher E., Kirsten A. Nyrop, Allison M. Deal, et al.. (2022). Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life. The Oncologist. 27(8). 694–702. 6 indexed citations
8.
Lichtman, Eben I., et al.. (2022). Localized light chain amyloidosis: A self-limited plasmacytic B-cell lymphoproliferative disorder. Frontiers in Oncology. 12. 1002253–1002253. 6 indexed citations
9.
Nakamura, Zev M., Christopher E. Jensen, Kirsten A. Nyrop, et al.. (2022). Prevalence and clinical correlates of cognitive impairment in adults with plasma cell disorders. Journal of Geriatric Oncology. 13(7). 987–996. 6 indexed citations
10.
Lichtman, Eben I., Hongwei Du, Peishun Shou, et al.. (2021). Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Clinical Cancer Research. 27(11). 3141–3153. 57 indexed citations
11.
Jensen, Christopher E., Kirsten A. Nyrop, Allison M. Deal, et al.. (2021). Geriatric-assessment-identified functional deficits among adults with multiple myeloma with normal performance status. Journal of Geriatric Oncology. 13(2). 182–189. 18 indexed citations
12.
Grant, Shakira J., Allison M. Deal, Hillary Heiling, et al.. (2021). A Cross-Sectional Analysis of County-Level Social Vulnerability and Physical Frailty Among Adults with Hematological Malignancies. Blood. 138(Supplement 1). 4130–4130. 4 indexed citations
13.
Grant, Shakira J., et al.. (2021). Social vulnerability and clinical trial access for older adults with myeloma in North Carolina.. Journal of Clinical Oncology. 39(15_suppl). e18540–e18540. 1 indexed citations
14.
15.
Sun, Chuang, Aruna Mahendravada, Brandon Ballard, et al.. (2019). Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget. 10(24). 2369–2383. 77 indexed citations
16.
Lichtman, Eben I. & Gianpietro Dotti. (2017). Chimeric antigen receptor T-cells for B-cell malignancies. Translational research. 187. 59–82. 19 indexed citations
17.
Jung, Dae Young, Hwi Jin Ko, Eben I. Lichtman, et al.. (2013). Short-term weight loss attenuates local tissue inflammation and improves insulin sensitivity without affecting adipose inflammation in obese mice. American Journal of Physiology-Endocrinology and Metabolism. 304(9). E964–E976. 34 indexed citations
18.
Lichtman, Eben I., Simon M. Helfgott, & Martin Kriegel. (2012). Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alpha. Clinical Immunology. 143(3). 210–221. 67 indexed citations
19.
Lichtman, Eben I., et al.. (2008). Primary Atmospheric Oxidation Mechanism for Toluene. The Journal of Physical Chemistry A. 113(1). 221–230. 71 indexed citations
20.
Berkers, Celia R., Martijn Verdoes, Eben I. Lichtman, et al.. (2005). Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nature Methods. 2(5). 357–362. 220 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Gelzleichter Breakdown of academic impact, for papers by Shripad Sinari Breakdown of academic impact, for papers by Zhongzheng Zhu Breakdown of academic impact, for papers by Xiaohong Chang Breakdown of academic impact, for papers by Chi-De Chen Breakdown of academic impact, for papers by Shwu‐Luan Lee Breakdown of academic impact, for papers by Erandi Rajagurubandara Breakdown of academic impact, for papers by Nigel J. Parr Breakdown of academic impact, for papers by Takashi Shinya Breakdown of academic impact, for papers by Rolf D. Pettersen
Rankless by CCL
2026